We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,224

U.S. Supreme Court Limits Venue Under the Patent Statute in TC Heartland
  • Paul Hastings LLP
  • USA
  • May 23 2017

On May 22, 2017, the United States Supreme Court, in TC Heartland LLC v. Kraft Foods Group Brands LLC, put an end to the swirling legal debate

Changes to pharmaceuticalbiopharmaceutical patent litigation in Canada
  • DLA Piper LLP
  • Canada
  • May 23 2017

As a result of the Comprehensive Economic Trade Agreement with the European Union, significant changes to the patent linkage provisions and patent

Uncertainty In Patent Term Extension For Biologics
  • Fish & Richardson PC
  • USA
  • May 22 2017

When Congress enacted the Biologics Price Competition and Innovation Act of 2009, it created an artificial act of infringement for the submission of a

Capitol Hill Healthcare Update
  • Baker & Hostetler LLP
  • USA
  • May 19 2017

Legislation reauthorizing FDA user fees for prescription and generic drugs, biosimilars, and medical devices won wide bipartisan approval last week in

Health Law Update - May 18, 2017
  • Baker & Hostetler LLP
  • USA
  • May 18 2017

Welcome to this week's edition of the Health Law Update. In this Issue Capitol Hill Healthcare Update Senate Panel OKs FDA User Fees Legislation

Congressional Panels Tackle FDA Reauthorization Act and Other Health Policy Issues
  • Reed Smith LLP
  • USA
  • May 12 2017

On May 11, 2017, the Senate on Health, Education, Labor, and Pensions (HELP) Committee approved S 934, a bill extend Food and Drug Administration

How Will The Supreme Court Choreograph The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • May 2 2017

On April 26, 2017, the Supreme Court heard oral arguments in Amgen v. Sandoz, where the parties have asked the Court to interpret two of the

Pfizer loses legal bid for information from Samsung Bioepis about biosimilar BRENZYS - What it means
  • Griffith Hack
  • Australia
  • May 1 2017

Pfizer has lost a bid in the Federal Court of Australia to access Samsung Bioepis' confidential material about how it produces its biosimilar BRENZYS

Sandoz v. AmgenBiosimilars at the Supreme CourtOral Argument
  • K&L Gates
  • USA
  • April 28 2017

All nine Supreme Court Justices heard argument on Wednesday, April 26, in Sandoz Inc., v. Amgen Inc. The Supreme Court is reviewing interpretations of

Sandoz v. Amgen Supreme Court Oral Argument
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • April 27 2017

On April 26, 2017, the U.S. Supreme Court heard oral arguments in Sandoz Inc. v. Amgen Inc., Nos. 15-1039, 15-1195, concerning Sandoz’s petition and